Kiniksa Pharmaceuticals International Plc’s filing revealed that its Officer Ragosa Mark acquired Company’s shares for reported $0.62 million on Aug 04 ’25. In the deal valued at $32.89 per share,18,889 shares were bought.
Then, Megna Michael R bought 17,000 shares, generating $549,936 in total proceeds.
Before that, KIMBERLY J. POPOVITS bought 64,508 shares. Kiniksa Pharmaceuticals International Plc shares valued at $1,928,596 were divested by the Director at a price of $29.90 per share.
Citigroup initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on March 13, 2025; the price target was $40. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid September with a ‘”a Buy”‘ rating. Wells Fargo began covering KNSA with “an Overweight” recommendation on May 03, 2024. BofA Securities maintained its rating on June 29, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Monday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock jump 3.03% to $32.95. Over the last five days, the stock has gained 21.86%. Kiniksa Pharmaceuticals International Plc shares have risen nearly 23.87% since the year began. Nevertheless, the stocks have risen 66.58% over the past one year.
How much short interest is there in Kiniksa Pharmaceuticals International Plc?
A steep rise in short interest was recorded in Kiniksa Pharmaceuticals International Plc stocks on 2025-07-15, growing by 0.17 million shares to a total of 2.53 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 2.36 million shares. There was a rise of 6.89%, which implies that there is a positive sentiment for the stock.
